Business Context and Reporting Period
OrthoPediatrics Corp. (Nasdaq: KIDS), a Delaware corporation, filed this Form 8-K on June 17, 2020, to report the entry into a material definitive agreement. The Company is an emerging growth company.
Key Financial Metrics and Transaction Details
This filing details a public offering of common stock rather than periodic financial results. Key transaction metrics include:
- Shares Offered: 1,600,000 shares of Common Stock.
- Public Offering Price: $47.00 per share.
- Underwriting Price: $44.18 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 240,000 additional shares.
- Estimated Net Proceeds: Approximately $70.3 million, or approximately $80.9 million if the over-allotment option is exercised in full.
- Underwriters: Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Lock-Up Provisions
The primary material change is the capital raise via the underwritten public offering. Additionally, the Company, its officers and directors, and Squadron Capital LLC (owner of 30.0% of outstanding Common Stock) have agreed to a 90-day lock-up period, prohibiting the sale or disposal of shares without written consent from the underwriters.
Outlook, Risks, and Management Commentary
The closing of the Offering is expected to occur on or about June 22, 2020, subject to customary conditions. The filing includes a cautionary note regarding forward-looking statements, highlighting specific risks including:
- Impact of the COVID-19 pandemic on product demand.
- The Company's ability to respond to pandemic-related challenges.
- Risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected June 22, 2020).
- Confirm whether the underwriters exercise the 30-day option to purchase the additional 240,000 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification obligations.
- Monitor the impact of the $70.3 million to $80.9 million in net proceeds on the Company's liquidity and balance sheet in subsequent filings.